Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Rationale for Performing Airway Clearance for Patients with Cystic Fibrosis

This activity will discuss rationale for performing airway clearance, current mechanical and pharmacologic choices, and therapies in the pipeline.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Airway clearance is the primary therapy for patients with cystic fibrosis.  In this activity, Dr. Zanni will discuss the rationale for performing airway clearance, as well as current mechanical and pharmacologic choices for patients.  He will also discuss airway clearance therapies that are making their way through the pipeline.  

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Explain the pathophysiologic rationale for performing airway clearance in patients with cystic fibrosis.
    2. Discuss mechanical and pharmacologic airway clearance therapies.
    3. Summarize cystic fibrosis guidelines for chronic pulmonary medications.
  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


    Robert L. Zanni, MD, CPI
    Section Chief, Pediatric Pulmonary Medicine
    Director, Cystic Fibrosis Center
    Unterberg Children's Hospital at Monmouth Medical Center

    Faculty’s disclosure:

    Dr. Zanni receives consulting fees from Vertex and fees for non-CME services from Gilead and Novartis.


    • Sean T. Barrett, CHCP has nothing to disclose.
    • Colleen Braun has nothing to disclose.
    • Kia K. Gray, MPH has nothing to disclose.
    • Nick Lombardi has disclosed he owns stock in Vertex.
    • Jennifer Spear Smith, PhD has nothing to disclose.
  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians, pulmonologists, registered nurses, nurse practitioners, dieticians, respiratory therapists, and social workers associated with cystic fibrosis care centers.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25  AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education

    Prova Education designs educational programs based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    No commercial support has been provided for this activity.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.